- Home
- IDAI vs BLRX Comparison
IDAI vs BLRX Comparison
Compare IDAI & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDAI | BLRX |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0M | 12.6M |
| IPO Year | 2022 | 2010 |
Fundamental Metrics
Financial Performance| Metric | IDAI | BLRX |
|---|---|---|
| Price | $2.76 | $2.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 31.7K | 8.1K |
| Earning Date | 05-15-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $103.06 | N/A |
| Revenue Next Year | $140.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.17 | $2.15 |
| 52 Week High | $5.28 | $4.56 |
Technical Indicators
Market Signals| Indicator | IDAI | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 48.61 |
| Support Level | $2.70 | $2.65 |
| Resistance Level | $2.80 | $3.02 |
| Average True Range (ATR) | 0.24 | 0.16 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 54.78 | 50.73 |
Price Performance
Historical ComparisonAbout IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The company operates in one reportable segment, artificial intelligence-powered solutions. The artificial intelligence-powered solutions segment generates revenue from software licenses, professional services, and recurring SaaS revenue.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.